CD8A and neoplasm: From these data, we concluded that mice challenged with tumorigenic MCA-205-OVA and MCA-205-E1A-Δp300-OVA tumor cells had a numerically more robust OVA-specific CD8 T cell response than mice challenged with the non-tumorigenic MCA-205-E1A-OVA tumor cells.